Literature DB >> 25056450

Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing.

Vishal Rajagopalan1, Muthukumar Vaidyanathan, Vanisree Arambakkam Janardhanam, James E Bradner.   

Abstract

Glioblastoma Multiforme (GBM) is an aggressive form of brain Tumor that has few cures. In this study, we analyze the anti-proliferative effects of a new molecule JQ1 against GBMs induced in Wistar Rats. JQ1 is essentially a Myc inhibitor. c-Myc is also known for altering the biochemistry of a tumor cell. Therefore, the study is intended to analyze certain other oncogenes associated with c-Myc and also the change in cellular biochemistry upon c-Myc inhibition. The quantitative analysis of gene expression gave a co-expressive pattern for all the three genes involved namely; c-Myc, Bcl-2, and Akt. The cellular biochemistry analysis by transmission electron microscopy revealed high glycogen and lipid aggregation in Myc inhibited cells and excessive autophagy. The study demonstrates the role of c-Myc as a central metabolic regulator and Bcl-2 and Akt assisting in extending c-Myc half-life as well as in regulation of autophagy, so as to regulate cell survival on the whole. The study also demonstrates that transient treatment by JQ1 leads to aggressive development of tumor and therefore, accelerating death, emphasizing the importance of dosage fixation, and duration for clinical use in future.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25056450     DOI: 10.1007/s10571-014-0083-4

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  40 in total

1.  Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation.

Authors:  S Cory; D L Vaux; A Strasser; A W Harris; J M Adams
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

2.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

Authors:  R Sears; F Nuckolls; E Haura; Y Taya; K Tamai; J R Nevins
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

Review 3.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

4.  Down-regulation of c-myc and bcl-2 gene expression in PU.1-induced apoptosis in murine erythroleukemia cells.

Authors:  F Kihara-Negishi; T Yamada; Y Kubota; N Kondoh; H Yamamoto; M Abe; T Shirai; Y Hashimoto; T Oikawa
Journal:  Int J Cancer       Date:  1998-05-18       Impact factor: 7.396

Review 5.  Links between metabolism and cancer.

Authors:  Chi V Dang
Journal:  Genes Dev       Date:  2012-05-01       Impact factor: 11.361

Review 6.  A matter of life and cell death.

Authors:  G Evan; T Littlewood
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

7.  Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition.

Authors:  Yongjun Fan; Kathleen G Dickman; Wei-Xing Zong
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

8.  Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1.

Authors:  Nuria Pescador; Diego Villar; Daniel Cifuentes; Mar Garcia-Rocha; Amaya Ortiz-Barahona; Silvia Vazquez; Angel Ordoñez; Yolanda Cuevas; David Saez-Morales; Maria Laura Garcia-Bermejo; Manuel O Landazuri; Joan Guinovart; Luis del Peso
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

9.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

10.  Inhibition of BET bromodomain targets genetically diverse glioblastoma.

Authors:  Zhixiang Cheng; Yuanying Gong; Yufang Ma; Kaihua Lu; Xiang Lu; Larry A Pierce; Reid C Thompson; Susanne Muller; Stefan Knapp; Jialiang Wang
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

View more
  6 in total

1.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

2.  Alisertib induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells.

Authors:  Zheng Liu; Feng Wang; Zhi-Wei Zhou; He-Chun Xia; Xin-Yu Wang; Yin-Xue Yang; Zhi-Xu He; Tao Sun; Shu-Feng Zhou
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

3.  Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells.

Authors:  Qiaoli Zhao; Andreana N Assimopoulou; Sabine M Klauck; Harilaos Damianakos; Ioanna Chinou; Nadine Kretschmer; José-Luis Rios; Vassilios P Papageorgiou; Rudolf Bauer; Thomas Efferth
Journal:  Oncotarget       Date:  2015-11-17

Review 4.  Epigenetics in cancer stem cells.

Authors:  Tan Boon Toh; Jhin Jieh Lim; Edward Kai-Hua Chow
Journal:  Mol Cancer       Date:  2017-02-01       Impact factor: 27.401

5.  Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells.

Authors:  Liping Han; Qingwei Zhao; Xianhong Liang; Xiaoqing Wang; Zhen Zhang; Zhiguo Ma; Miaoqing Zhao; Aihua Wang; Shuai Liu
Journal:  Oncotarget       Date:  2017-07-11

6.  The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.

Authors:  L L da Motta; I Ledaki; K Purshouse; S Haider; M A De Bastiani; D Baban; M Morotti; G Steers; S Wigfield; E Bridges; J-L Li; S Knapp; D Ebner; F Klamt; A L Harris; A McIntyre
Journal:  Oncogene       Date:  2016-06-13       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.